To evaluate the effects of dezocine on the prevention of postoperative catheter-related bladder discomfort (CRBD). Ninety-six adult patients undergoing abdominal surgery with urinary catheterization under general anesthesia were randomized into dezocine and control (flurbiprofen) groups. The postoperative CRBD, pain score, sedation score and adverse effects were evaluated at 0, 1, 2 and 6 hrs after tracheal extubation. The primary outcome showed a lower incidence of CRBD at 1 hr post-extubation in the dezocine group (29.17%) than the control group (58.33%, <0.01). The incidences at 0 and 2 hrs post-extubation and the overall incidence were also lower in the dezocine group than the control group (all <0.05). The severity of CRBD at 0, 1, 2 and 6 hrs and the pain, sedation score and other adverse effects were comparable between the two groups (>0.05); however, the overall severity of CRBD was decreased in the dezocine group compared with the control group (<0.05). Intraoperative dezocine reduces the incidence and severity of postoperative CRBD without clinically relevant adverse effects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497880 | PMC |
http://dx.doi.org/10.2147/DDDT.S199897 | DOI Listing |
Am J Transl Res
December 2024
Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Cancer, Nanfang Hospital, Southern Medical University Guangzhou 510515, Guangdong, China.
Objective: Gastric cancer is a prevalent and significant malignancy that occurs throughout the world, with a particularly pronounced impact on the elderly population. This study aims to compare the efficacy of nalbuphine and dezocine in managing pain following laparoscopic radical gastrectomy.
Method: Elderly patients undergoing laparoscopic radical gastrectomy were divided into a nalbuphine (n=50) group and a dezocine (n=50) group according to their anesthesia agent.
Oncol Lett
March 2025
Department of Anesthesiology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang 323000, P.R. China.
Flurbiprofen axetil is a nonsteroidal anti-inflammatory drug used for analgesia. Its combination with dezocine has previously shown a superior postoperative analgesic effect compared with that of opioids. The present study compared the analgesic effect between dezocine plus flurbiprofen axetil (DFA) and sufentanil in patients with colorectal cancer (CRC) following resection of the tumor.
View Article and Find Full Text PDFCNS Neurosci Ther
September 2024
Department of Anesthesiology and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Aims: Opioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under-utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely.
View Article and Find Full Text PDFBMC Anesthesiol
September 2024
Department of Anesthesiology, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, 29 Bulan Road, Shenzhen, 518112, Guangdong, China.
Front Pharmacol
July 2024
Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders and National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Anhedonia and motivational impairments are cardinal features of depression, against which conventional antidepressants demonstrate limited efficacy. Preclinical investigations and extant clinical trial data substantiate the promise of opioid receptor modulators in addressing anhedonia, depression, and anxiety. While synthetic opioid agents like dezocine are conventionally employed for analgesia, their distinctive pharmacological profile has engendered interest in their potential antidepressant properties and translational applications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!